Paper32201284
Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
Cucchetti A and 16 others. J Hepatol, 2020. Cited by 67 papers, by iCite.
Cite this record
ConductScience Library. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. Papers, record 32201284. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32201284
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Liver Transplantation | Major topic |
| Neoadjuvant Therapy | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Technology, Radiologic | Major topic |
| Cause of Death | |
| Female | |
| Humans | |
| Kaplan-Meier Estimate | |
| Male | |
| Middle Aged | |
| Postoperative Complications | |
| Predictive Value of Tests | |
| Prognosis | |
| Risk Assessment | |
| Tumor Burden | |
| Ultrasonography | |
| alpha-Fetoproteins |
Source PubMed
Cited by40
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 67 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42008358 | SREBP2 as a Novel Biomarker for Posttransplant Hepatocellular Carcinoma Recurrence: A New Prognostic Nomogram. | Biomed Res Int | 2026 | https://conductscience.org/library/papers/42008358 | PubMed |
| 41999190 | A Clinical-Radiomics Nomogram Predicts Early Tumor Necrosis After Transarterial Chemoembolization for Hepatocellular Carcinoma. | Technol Cancer Res Treat | 2026 | https://conductscience.org/library/papers/41999190 | PubMed |
| 41301037 | Transforming Liver Cancer Therapy: Integrating Molecular Profiling with Precision and Transplant-Based Care. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41301037 | PubMed |
| 40721563 | Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40721563 | PubMed |
| 40427217 | The Italian Score for Organ Allocation: A Ten-Year Monocentric Retrospective Analysis in Liver Transplantation for Hepatocellular Carcinoma. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40427217 | PubMed |
| 40380811 | Liver transplantation as a treatment for cancer: comprehensive review. | BJS Open | 2025 | https://conductscience.org/library/papers/40380811 | PubMed |
| 39494583 | New Scenarios in Liver Transplantation for Hepatocellular Carcinoma. | Liver Int | 2025 | https://conductscience.org/library/papers/39494583 | PubMed |
| 38983320 | Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer. | World J Gastrointest Surg | 2024 | https://conductscience.org/library/papers/38983320 | PubMed |
| 38829544 | Combined transarterial chemoembolization and thermal ablation in candidates to liver transplantation with hepatocellular carcinoma: pathological findings and post-transplant outcome. | Radiol Med | 2024 | https://conductscience.org/library/papers/38829544 | PubMed |
| 38606106 | A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. | Front Oncol | 2024 | https://conductscience.org/library/papers/38606106 | PubMed |
| 38473400 | Impact of Pre-Liver Transplant Treatments on the Imaging Accuracy of HCC Staging and Their Influence on Outcomes. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38473400 | PubMed |
| 38435683 | A Deep Learning Model Combining Multimodal Factors to Predict the Overall Survival of Transarterial Chemoembolization. | J Hepatocell Carcinoma | 2024 | https://conductscience.org/library/papers/38435683 | PubMed |
| 38137868 | Hepatocellular Carcinoma: Optimal Radiological Evaluation before Liver Transplantation. | Life (Basel) | 2023 | https://conductscience.org/library/papers/38137868 | PubMed |
| 37370775 | Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37370775 | PubMed |
| 37039979 | Quantitative Prediction of Posttransplant Hepatocellular Carcinoma Prognosis Using ADV Score: Validation with Korea-Nationwide Transplantation Registry Database. | J Gastrointest Surg | 2023 | https://conductscience.org/library/papers/37039979 | PubMed |
| 37034235 | Main factors influencing long-term outcomes of liver transplantation in 2022. | World J Hepatol | 2023 | https://conductscience.org/library/papers/37034235 | PubMed |
| 36967432 | The predictive value of the modified AFP model for liver transplantation outcomes in multinodular hepatocellular carcinoma patients. | World J Surg Oncol | 2023 | https://conductscience.org/library/papers/36967432 | PubMed |
| 36849836 | Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma. | Cardiovasc Intervent Radiol | 2023 | https://conductscience.org/library/papers/36849836 | PubMed |
| 36691474 | AFP score and metroticket 2.0 perform similarly and could be used in a "within-ALL" clinical decision tool. | JHEP Rep | 2023 | https://conductscience.org/library/papers/36691474 | PubMed |
| 36514693 | Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress. | J Hepatocell Carcinoma | 2022 | https://conductscience.org/library/papers/36514693 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32201284
GET https://conductscience.org/api/papers/v1/32201284/cited_by?page=2